Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
04/2012
04/17/2012US8158132 used to control the interaction of particular cell types with their external environment; for chronic pain; reduced side effects, long-lasting actions that do not require frequent injections or long-term catheterization; does not lead to tolerance and associated dependence
04/17/2012US8158131 Recombinant dengue virus antigens comprising the C15 signal peptide, full-length PRM protein, and full-length E protein
04/17/2012US8158130 Method for the preparation of virus-like particles (VLPS) comprising heterologous multiple membrane spanning proteins
04/17/2012US8158129 Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
04/17/2012US8158127 Compounds for neutralizing the effects of secreted PLA2 IIA
04/17/2012US8158126 Stem cell fusion model of carcinogenesis
04/17/2012US8158125 B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases
04/17/2012US8158123 Suppressing bone resorption; inhibiting expression of osteoclast associated gene selected from OC 1-285, sequences 4, 34, 38 and/or 43
04/17/2012US8158107 Genes and proteins associated with angiogenesis and uses thereof
04/17/2012CA2543659C Useful immunotherapeutic agent for the combined treatment of tuberculosis in association with other drugs
04/17/2012CA2510664C Anthracycline-antibody conjugates
04/17/2012CA2506672C Il-23 for treating cutaneous wounds
04/17/2012CA2492671C Humanized antibody and process for preparing same
04/17/2012CA2481521C Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
04/17/2012CA2452720C Vaccines comprising aluminium adjuvants and histidine
04/17/2012CA2431600C Molecules with extended half-lives, compositions and uses thereof
04/17/2012CA2408328C Immunogenic polypeptides encoded by mage minigenes and uses thereof
04/17/2012CA2377607C Neurotrophic factor receptor
04/17/2012CA2372181C Adjuvant combination formulations
04/17/2012CA2355495C Method of modulating tumor immunity
04/17/2012CA2347928C Cell surface molecule-induced macrophage activation
04/17/2012CA2202090C Papilloma virus-like particles, fusion proteins as well as processes for their production
04/17/2012CA2145778C Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
04/12/2012WO2012048333A1 Oral vaccine fast-dissolving dosage form using starch
04/12/2012WO2012048246A1 Reduction of antibody response against botulinum neurotoxin and variants thereof
04/12/2012WO2012048190A1 Annexin ii compositions and methods
04/12/2012WO2012048134A2 Methods for treating psoriasis
04/12/2012WO2012048125A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
04/12/2012WO2012047954A1 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
04/12/2012WO2012047941A2 Hemagglutinin polypeptides, and reagents and methods relating thereto
04/12/2012WO2012047732A2 Antibody compositions and methods of use
04/12/2012WO2012047724A1 Antibody drug conjugates (adc) that bind to 191p4d12 proteins
04/12/2012WO2012047706A2 Methods for promotiing reinnervation of auditory hair cells
04/12/2012WO2012047664A1 Anti-pecam therapy, compositions, methods, and uses
04/12/2012WO2012047629A2 Selective removal of age-modified cells for treatment of ather0sclerosis
04/12/2012WO2012047427A2 Antibodies for botulinum neurotoxins
04/12/2012WO2012047317A2 Tumor specific antibodies and uses therefor
04/12/2012WO2012047294A2 Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
04/12/2012WO2012047267A2 Polyvalent immunogen
04/12/2012WO2012047265A2 Improved adjuvant system for vaccine administration
04/12/2012WO2012046745A1 Therapeutic agent for malignant tumors expressing mhc class ii
04/12/2012WO2012046260A1 Use of a phosphopeptide able to block her3/p85 interaction for the treatment of her2 hyper-expressing tumours
04/12/2012WO2012046081A1 Malaria vaccine
04/12/2012WO2012046009A1 Composition for intraocular implantation of bevacizumab
04/12/2012WO2012046006A2 Cancer targets
04/12/2012WO2012046001A1 Method to inhibit recruitment of monocytes and macrophages by an icam-3 inhibitor
04/12/2012WO2012045882A2 Pharmaceutical composition
04/12/2012WO2012045848A1 Methods of treating psoriasis using il-17 antagonists
04/12/2012WO2012045752A1 Cd33 binding agents
04/12/2012WO2012045473A1 Viruses for the treatment of fibrosis
04/12/2012WO2012045281A1 Diagnostic and therapeutic uses of moesin fragments
04/12/2012WO2012045274A1 Moesin modulators and uses thereof
04/12/2012WO2012045157A1 Arih2 regulates dendritic cell activation and autoimmunity
04/12/2012WO2012045150A1 Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
04/12/2012WO2012045115A1 Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders
04/12/2012WO2012020123A3 Neuropilin as a biomarker for bevacizumab combination therapies
04/12/2012WO2012018801A9 Suppressing bone loss with anti-il-19 antibody
04/12/2012WO2012017327A3 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
04/12/2012WO2012017323A3 Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
04/12/2012WO2012009442A3 Anti-addl monoclonal antibody and uses thereof
04/12/2012WO2012007880A3 Modified single domain antigen binding molecules and uses thereof
04/12/2012WO2012007846A3 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
04/12/2012WO2012003361A3 Nanoemulsion vaccines
04/12/2012WO2011163452A9 Treating surface of the eye disorders
04/12/2012WO2011153209A9 Cd36 inhibition to control obesity and insulin sensitivity
04/12/2012WO2011133424A3 Genetic amplification of iqgap1 in cancer
04/12/2012WO2011133210A3 A method treating breast cancer
04/12/2012WO2011130650A3 Antibodies for the treatment of clostridium difficile-associated infection and disease
04/12/2012WO2011127291A3 Compositions and methods for the treatment of a neoplasia
04/12/2012WO2011103330A3 Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury
04/12/2012WO2011100477A3 Antibodies and processes for preparing the same
04/12/2012WO2011077245A3 Composition comprising an oxysterol modulator and a cd25 - depleting monoclonal antibody for treating cancer
04/12/2012US20120090043 Targets for retrovirus associated diseases
04/12/2012US20120090041 Compositions and Methods for Inhibiting Endogenous Immunoglobulin Genes and Producing Transgenic Human Idiotype Antibodies
04/12/2012US20120089541 Biomarkers and methods of treatment
04/12/2012US20120089084 Wound healing device
04/12/2012US20120089076 Method for treating inflammation
04/12/2012US20120088297 Mycobacterial antigens expressed under low oxygen tension
04/12/2012US20120088287 Cripto antagonism of activin and tgf-b signaling
04/12/2012US20120088255 Her-2 binding antagonists
04/12/2012US20120087976 Adjuvant compositions comprising a non-ionic isotonicity agent
04/12/2012US20120087956 Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
04/12/2012US20120087946 Recombinant bacterium and methods of antigen and nucleic acid delivery
04/12/2012US20120087945 Method for keeping an immunogenic composition available for administration to an animal
04/12/2012US20120087944 Oral vaccine fast-dissolving dosage form using starch
04/12/2012US20120087940 Vector for treating alzheimer's disease
04/12/2012US20120087939 Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection
04/12/2012US20120087938 Consensus/ancestral immunogens
04/12/2012US20120087937 Novel compositions
04/12/2012US20120087936 Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
04/12/2012US20120087934 Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
04/12/2012US20120087932 Diagnostic test for virus
04/12/2012US20120087931 Therapeutic and diagnostic anti-hsp70 antibodies
04/12/2012US20120087930 Marker of Streptococcus Anginosus/ Streptococcus Constellatus (MOAC) and Uses Thereof
04/12/2012US20120087929 VEGF Antagonist Formulations for Intravitreal Administration
04/12/2012US20120087928 Therapeutics for age-related macular degeneration
04/12/2012US20120087927 Antibody containing igg2 having amino acid mutation introduced therein
04/12/2012US20120087926 Chicken-derived anti-lox-1 antibody
04/12/2012US20120087925 Method for the treatment of inflammatory disorders
04/12/2012US20120087924 Recombinant B. pseudomallei Adhesin Protein and Methods and Uses Thereof
1 ... 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 ... 1823